Search

Orciprenaline

A beta-adrenergic agonist used in the treatment of asthma and bronchospasms. [PubChem]

Eflapegrastim

[A252320] It typically develops during the first cycle of chemotherapy and is associated with an increased risk of morbidity and mortality. … in which the patient develops an infection during a period of significant neutropenia.

Mesoridazine

A phenothiazine antipsychotic with effects similar to chlorpromazine.

Montmorillonite

Aurothioglucose

Contemporary research on the effect of gold salts treatment began in 1935, primarily to reduce inflammation and to slow disease progression in patients with rheumatoid arthritis [A32326]. … The use of gold compounds has decreased since the 1980s owing to numerous side effects, limited efficacy, and slow onset of action.

Garadacimab

[L53283,A273998] Garadacimab received its first approval in Australia and the UK in January 2025, and has since been approved in a number of other jurisdictions, including the EU and Japan. … [A273993] In June 2025, garadacimab was approved by the US FDA for the prophylaxis of HAE episodes in patients ≥12 years of age.

Rapacuronium

Rapacuronium was withdrawn in 2001 in many countries due to risk of fatal bronchospasm.

Deutetrabenazine

Decreased plasma fluctuations of deutetrabenazine due to attenuated metabolism may explain a lower incidence of adverse reactions associated with deutetrabenazine [A32042]. … In clinical trials of patients with HD, 12 weeks of treatment of deutetrabenazine resulted in overall improvement in mean total maximal chorea scores and motor signs than placebo [A32046].

Aceclidine

, and lens anterior displacement, leading to reduced risk of retina or vitreous tractions. … Aceclidine is a cholinergic muscarinic agonist which began marketing in Europe in the 1970s for the treatment of glaucoma.

Ibutilide

It is indicated for the conversion of acute atrial flutter and recent onset atrial fibrillation to normal sinus rhythm (NSR). … Ibutilide is a Class III antiarrhythmic agent available in intravenous formulations.